The devastating pandemic of SARS-CoV-2 (COVID-19) began in Wuhan, China, and spread rapidly through most parts of the world in the second half of 2020. The air droplet spread of SARS-CoV-2 is of great global health concern as it is potentially fatal. Various drugs and treatment modalities have been tried to date, but none have been found to be definitive. Tranexamic acid (TXA) is commonly used in pigmentary disorders in dermatology due to its ability to reduce melanocyte tyrosinase activity. It also possesses anti-fibrinolytic and anti-inflammatory properties, which have been observed to suppress the cytokine storm and modulate coagulopathy in patients suffering from COVID-19. TXA, when administered early, has been effective in decreasing the severity of symptoms in COVID-19 patients, but on the contrary, it has also been associated with life-threatening thrombosis when given as a single drug.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682518 | PMC |
| http://dx.doi.org/10.32592/ARI.2024.79.3.459 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of Inhalational Tranexamic Acid in Patients with Nonmassive Hemoptysis-A Systematic Review and Meta-Analysis.
Lung
January 2025
Department of Emergency Medicine, Aarupadai Veedu Medical College and Hospital, Vinayaka Missions Research Foundation, Puducherry, India.
Background: Hemoptysis, the expectoration of blood from the lower respiratory tract, varies in severity and necessitates effective management to mitigate morbidity. Traditional treatments include bronchial artery embolization and pharmacological approaches. Tranexamic acid (TXA), an antifibrinolytic agent known for its efficacy in reducing bleeding during surgery and trauma, is being explored for its efficacy in treating Hemoptysis via both intravenous and inhalational routes.
View Article and Find Full Text PDFIntegrative analyses of mendelian randomization and bioinformatics reveal casual relationship and genetic links between COVID-19 and knee osteoarthritis.
BMC Med Genomics
January 2025
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing, 400016, China.
Background: Clinical and epidemiological analyses have found an association between coronavirus disease 2019 (COVID-19) and knee osteoarthritis (KOA). Infection with COVID-19 may increase the risk of developing KOA.
Objectives: This study aimed to investigate the potential causal relationship between COVID-19 and KOA using Mendelian randomization (MR) and to explore the underlying mechanisms through a systematic bioinformatics approach.
Tranexamic Acid and Blood Transfusion in Liver Resection-Reply.
JAMA
January 2025
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Tranexamic Acid and Blood Transfusion in Liver Resection.
JAMA
January 2025
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.
Total hip arthroplasty was found to be safe in Jehovah's Witness patients: a multi-centered matched study.
Arch Orthop Trauma Surg
December 2024
Duke University Health System, Durham, USA.
Background: Jehovah's Witness patients refuse blood transfusion because of their religious beliefs making total hip arthroplasty (THA) challenging. This study aims to determine the safety of THA in Jehovah's Witness patients using standard perioperative protocols as well as evaluate the effectiveness of tranexamic acid (TXA) in controlling blood loss.
Methods: Databases from two tertiary academic centers were queried from 2003 to 2021 to identify THA patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!